#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau





#### (43) International Publication Date 8 August 2002 (08.08.2002)

#### **PCT**

# (10) International Publication Number WO 02/060495 A1

(51) International Patent Classification<sup>7</sup>: A61F 9/00, A61K 9/00

A61L 12/08,

(21) International Application Number: PCT/NL02/00012

(22) International Filing Date: 9 January 2002 (09.01.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 1017060

9 January 2001 (09.01.2001) NL

(71) Applicant and

(72) Inventor: WAGENAAR, Louis, Johan [NL/NL]; Joop den Uyllaan 3, NL-2314 GC Leiden (NL).

(74) Agent: 'T JONG, Bastiaan, Jacobus; Arnold & Siedsma, Sweelinckplein 1, NL-2517 GK The Hague (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

02/060495 A1

#### (54) Title: PROCEDURE AND COMPOSITION OF TREATMENT AND/OR CARE OF THE EYE

(57) Abstract: The invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and eye-care wherein the lenses are impregnated with a suitable composition. The invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses. The invention further provides a method for the treatment and/or care and/or protection of the eye comprising wearing contact lenses impregnated with a suitable composition and a composition for disinfection and/or conservation of eye care products.

>

# Procedure and Composition of Treatment and/or Care of the Eye

The current invention provides a procedure for the manufacture of contact lenses for eye treatment, eye protection and/or eye-care. The invention also provides a composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, a kit containing such a composition and one or more contact lenses as well as contact lenses impregnated with the composition.

Because they regularly have unusual objects in 10 their eyes for years contact lens wearers have a higher chance of damaging their cornea, eye-stratum, the endothelium or other parts of the eyes than non-wearers, for example because chemical substances which (may) irritation or damage to the eye could be released from 15 the lens or the surface of the lens after inserting the lens into the eyes. Lenses which have not been properly cleaned or damaged lenses as well as dust-particles, traces of sand or pollen which have gotten under the lens could also affect the cornea. These damages or irritati-20 ons can be superficial and temporary, but could also result in far-reaching consequences since usually worn daily. Health risks could occur, from irritated and red eyes to serious complications such as permanent damage of the cornea resulting in blindness.

The cause of such complications is multifarious. Placing the contact lens onto the eye disturbs its physiological condition. After habituation a new balance will be reached that can be disturbed again by various factors, such as ageing of the contact lens, damage to and deposit on the lens, change of tear-flow with respect to composition and quantity due to frequency and manner of winking, chemical toxicity of substances the user is in contact with, mechanical pressure and chronic lack of oxygen. The ageing of the user may bring about changes in

2

his or her eyes thereby disturbing the physiological balance. The use of medication or the development of allergies may also lead to irritations or damage of (parts of) the eyes.

Because nowadays contact lenses are frequently used for longer periods of time careful and regular cleaning has become more important. If this is not done sufficiently for instance bacteria, proteins etc. may cause irritations and damage (more promptly). To prevent permanent damage it is vital that possible damage to the cornea or other parts of the eyes is treated as soon as possible.

Moreover, contact lens wearers may need to extra protect their eyes. It could be useful to the eyes 15 to dispose of extra nutrition, such as vitamins and provitamins or (also) those substances which offer protection or allow, support or accelerate the repair of an occurring damage. In eye healthcare several products are known to assist in the (accelerated) recovery of the 20 soundness of the cornea. These products, however, usually have to be administered (dripped in or applied onto the eye) separately or have to be swallowed by the user.

It is the aim of the current invention to provide the opportunity for a long-term care or treatment 25 and/or protection and/or care of the eyes.

Considering the possibilities of irritation and damage to the cornea, the stratum, the endothelium or other parts of the eyes are manifold, one requires protection, conditioning and ,whenever possible, restoration of the sustained damage to the eye. The current invention therefore provides a method for the manufacture of contact lenses for the treatment and/or care and/or protection of the eyes, comprising the impregnation of contact lenses in a solution which contains suitable compounds for the treatment and/or care and/or protection of the eyes. By wearing contact lenses the compounds which treat and/or protect and/or care of the eyes will be in contact with (part of) the eyes. This way the lens will be a

3

method of administering these compounds which will often imply a more long-lasting administering compared to current eye-drops. The compounds mentioned can be either absorbed into the lens material or be attached to them or 5 both. The term 'impregnate' in this application refers to either of these or to a combination of both.

Furthermore the current invention provides a composition for the impregnation of contact lenses for the treatment and/or care and/or protection of the eyes, 10 comprising compounds suitable for eye treatment or care or protection.

The current invention offers various types of compounds dependent on the type of treatment, care or protection required. For the benefit of the user these compositions can be combined with the compounds usually used for disinfecting, cleaning, insertion, moisturizing, rinsing or storing of contact lenses, so that the user need not add these compounds separately. However, it is likewise possible to just impregnate the lenses with the above-mentioned care or treatment products to prevent damage caused by (other) cleaning-agents or disinfectants.

Compounds that can be applied, but are not limited to substances which feed or treat the eye or may 25 improve, accelerate or initiate local damage repair, or (helps to) avoid local damage or irritations of (parts of) the eye, are: for instance (dex)pantenol, pantothenic acid, hyaluron acid, retinol (Vitamin A) and retinyl derivatives, carotene, thiamine (Vitamin B1), riboflavine 30 (Vitamin B2), pyridoxine (Vitamin B6), nicotinic acid, nicotine acidamin, biotine (Vitamin B7), niacinamide and niacine (vitamin B3), ascorbic acid (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatin, taurin, serine 35 protease and other enzymes, propamidines, Vitamine D and its derivatives such as calciferol, Vitamin K, tannin, pyruates, fibroplastin, fibronectine and fibrohydrolysate, heparin, alfa-ketaglutarine acid, carnisin, lamini-

4

sin, mucin, tenascin, peptides ,EGF, PDGF, FGF and all ophtalmologically acceptable salts and derivatives of the compounds mentioned above, selenium, calcium, zinc and other minerals.

Products used for maintenance and storage of contact lenses, like cleaning products and disinfecting solutions, and sprays, so-called all-in-one solutions, storage liquids and rinsing liquids, insertion solutions and moisturizers, neutralizers in either liquid or tablet form, gels, coatings and tablets which either make or assist in making contact lens solutions or make solutions come into being or are used for or in such solutions.

According to the current invention the composition can therefore appear in various forms, such as a solution, spray or tablet which after dissolution makes a solution. Compounds intended for the care of contact lenses may also be part of a tablet which is combined with a solution that contains the care, treatment or protection agent or the reverse. Obviously both could also be included in one tablet or in separate tablets. Even so compounds can be included in a solution that is (to be) mixed with a solution without a compound.

Since the current substances which necessarily have to be applied for their germicidal and preservative ' 25 effects in eye-care solutions, eye-drops and contact lens care solutions and which are germicidal in a short period of time and sufficiently limiting increase in germ population usually have the disadvantage of causing irritation or even attacking the eye to a large or lesser degree 30 it would be greatly advantageous to use compounds in eyecare solutions, eye-drops and contact lens solutions for germicidal or conservation purposes which are non-irritant or protect against these irritations or damages. Possible damage and irritation of the cornea or other 35 parts of the eye will thus be avoided. An additional aim of the current invention is to disclose a method for improvement of the way a desired (and often necessary) antibacterial effect of a composition for contact lens

5

care or eye-care/eye-drops can be reached. A number of peptides are naturally found in the eye. They have a protective effect on the eye and particularly the cornea. The use of peptides in a composition for use in a contact lens solution, but also in eye-drops, could be greatly advantageous, because many peptides do not cause damage to the cornea; to some extend they also offer protection. They also offer protection from and support against bacterial infections, especially for people prone to such infections or people whose corneas are (easily) damaged.

According to the current invention peptides can be used separately or in combination with other eye-care products or treatments.

The composition according to the current inven15 tion can be applied when impregnating all kinds of contact lenses, especially and preferably soft lenses, but
also hard lenses, disposable lenses and long-lasting ones
as well as extended wear lenses and intra-ocular lenses
would benefit. Impregnation can be carried out by the
20 user, for instance during maintenance, but also, as with
new lenses, in the delivery packaging.

is not necessary for the user using the contact lenses according to the current invention to be already familiar with wearing lenses. People, and even 25 animals, who in fact do not need any eye-correction, but who require for instance certain nutrients for the eye or products to (possibly) set off, support or accelerate healing sores or injuries could wear contact lenses or similar objects according to the current invention on or 30 in the eye to facilitate the required compound(s) on or into the eye. It is not necessary for the active component with which contact lenses have been impregnated to repair or prevent any damage. Also medicines can be administered through a contact lens according to the 35 current invention. An example of another type of effective compound, in this case a medicine, which could be administered advantageously to the eye according to the current invention is for instance cromoglycate. This

6

compound works as a precautionary protection against allergies. A contact lens with this compound could be used when the user expects an allergic reaction, for example in a period with high levels of pollen. Other compounds can be used as well to either prevent or reduce allergic reactions, such s emedastine, azelastine and nedocromil.

Other applications of contact lenses according to the current invention could be found in the treatment of so-called 'dry eyes' or irritated or red eyes, hence called 'dry eyes'. Currently mainly eye-drops are used to treat this. Such eye-drops, however, usually offer only short-term relief. In order to lengthen the availability of the active agents for the treatment of the eyes several complex or expensive possibilities for slow-release eye-drops have been proposed. The contact lenses according to the current invention offer a simple, cheap and elegant alternative.

It could be particularly advantageous to use 20 the compounds suggested in the current invention as giving relief to dry eyes in combination with polymers from which is known or believed that they, when used in eye-drops, offer relief, such as polymers of the type PVP, PVA, HPMC, HPC, Carbomere or Dextrane.

As mentioned above contact lenses according to the current invention can also be used to apply substances which cure or correct eye-diseases or disorders and which should be administered once or several times a day to take sufficient effect at least part of the day. The use of contact lenses according to the current invention could be effective here. Moreover, the use of contact lenses will generally result in a more constant level of the effective agent at the point of application than would have been possible with the use of eye-drops or even eye-balm. Eye-balm also has the disadvantages of causing limited eyesight directly after application and a less easy way of application for some users compared to applying contact lenses. For wearers of contact lenses

the use of the current invention with their own lenses is particularly economical, because they do not need to perform any supplementary actions.

An advantage of the current invention is that

5 the price of contact lenses has dropped considerably over
the last few years especially that of short-term use
lenses such as the so-called day-lenses, week-lenses,
month-lenses or three-months'-lenses. Such lenses are a
preferable embodiment of the current invention.

The current invention will be illustrated in the following examples:

#### EXAMPLES

Examples of compositions to be used in the 15 procedure according to the current invention are the following:

- A. All-in-one solutions:
- 20 1. PHMB HCl 2.5 ppm
  - 2. Boric Acid 0.75%
  - 3. Borax 0.15%
  - 4. NaCl 0.40%
  - 5. EDTA-Na 0.03%
- 25 6. HPMC 10,000 0.10%
  - 7. Dexpantenol 1.0%
  - 8. pH adaptation with NaoH or HCL ad pH 7.4
  - B. Neutralizers (tablets):

30

- 1. Catalase 3000 IU
- 2. KH2PO4 50 mg
- 3. K2hPO4 150 mg
- 4. NaCl q.s.
- 35 5. Na-EDTA 0.2 mg
  - 6. Collagene 5 mg
  - 7. PVP K 90 10 mg

8

- C. Storage solutions and insertion solutions:
- 1. HPMC 4000 cP 0.2 %
- 2. Citric Acid 0.5 %
- 5 3. Na citrate 1.0 %
  - 4. NaCl ad 300 mOsm
  - 5. Na-EDTA 0.02 %
  - 6. Alexidine 2 HCL 0.5 ppm
  - 7. Hyaluronic Acid 0.25 %
- 10 8. pH adaptation with NaOH or HCL ad pH 7.2

BNSDOCID: <WO\_\_\_\_02060495A1\_I\_>

9

#### Claims

- Method for the production of contact lenses for the treatment and/or care and/or protection of the eye, comprising the impregnation of contact lenses in a solution which contains suitable components for the treatment and/or care and/or protection of the eye.
- 2. Composition for the impregnation of a contact lens for the treatment and/or care and/or protection of the eye, comprising one or more suitable components for eye-treatment and/or care and/or protection of the 10 eye.
- Composition of claim 2. characterized in that for the treatment and/or care and/or protection of the eye at least one suitable component is selected from the group of: (dex)pantenol, pantothenic acid, hyaluron 15 acid and its salts and derivatives, retinol (Vitamin A) and retinol derivatives, carotenes, thiamines (Vitamin B1), riboflavine (Vitamin B2) pyridoxine (Vitamin B6), nicotinic acid, nicotinic acidamide, biotin (Vitamin B7), niacinamide and niacine (Vitamin B3), ascorbin 20 (Vitamin C) and other anti-oxidants, saccharose, honey and other bee products, red beetroot syrup, collagen, gelatine, taurine, serine protease and other enzymes, propamidines, Vitamin D and its derivatives calciferol, Vitamin K, tannin, pyruvates, fibroplastine, 25 fibronectin, fibronectinhydrolysate, heparin, alfa-ketoglutaric acid, carnisine, laminisine, mucin, tenascin, peptides, EGF, PDGF, FGF, sugaresters and all pharmaceutically acceptable salts and derivatives of the compounds
  - 4. Composition of claims 2 or 3 further containing compounds to disinfect, clean, insert and/or store contact lenses.

mentioned above, as well as selenium, calcium, zinc and

30 other minerals.

- 5. Composition of claim 4 characterized in that it contains one or more peptides as component to disinfect, protect, clean and/or store the contact lenses.
- 6. Composition of claims 2-5 characterized in 5 that the suitable component for eye-treatment is a medicine.
- 7. Composition according to claim 6 characterized in that the medicine is chosen from the group of cromoglycin acid, Edamastine, azelastine and nedrocromil 10 and their ophtalmologically acceptable salts and derivatives.
  - 8. Composition of claims 2-7 characterized in that the composition takes the form of a spray, solution, gel, coating and/or tablet.
- 9. Contact lens for treatment and/or care and/or protection of the eye impregnated with a composition of claims 2-8.
- 10. A kit for the production of contact lenses for the treatment and/or care of the eye, comprising one 20 or more kits of contact lenses and the composition of claims 2-8.
- 11. Method for the treatment and/or care and/or protection of the eye comprising the wearing of the contact lenses according to claim 9 for a set period of 25 time.
  - 12. Method of claims 11 for the treatment or prevention of dry eyes.
  - 13. Method of claim 11 for the treatment or prevention of allergic symptoms.
- 30 14. Method of claim 11 for the treatment of eye-diseases.
- 15. Composition for disinfection and/or conservation of contact lenses or eye-care products or eye-drops characterized in that they contain at least one 35 peptide and or a sugarester.

PCT/NL 02/00012

		FCIFNL	. 02/00012		
A. CLASS IPC 7	ification of subject matter A61L12/08 A61F9/00 A61K9/0	00			
According to	o International Patent Classification (IPC) or to both national classific	eation and IPC			
	SEARCHED				
IPC 7	ocumentation searched (classification system followed by classificat A61L	,			
	tion searched other than minimum documentation to the extent that		•		
WPI Da	ata base consulted during the international search (name of data ba	ise and, where practical, search terms	rzeq)		
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT		· ·		
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages	Relevant to claim No.		
	·				
Х	DATABASE WPI Week 198837	25	1		
	Derwent Publications Ltd., Londo AN 1988-262735 XP002195280				
	& SU 1 377 104 A (KBME-R KUIB ME 29 February 1988 (1988-02-29) abstract	D INST),			
	, 500 Ann Gast				
X	DATABASE WPI Week 199649 Derwent Publications Ltd., London, GB; AN 1996-495831 XP002195281 & RU 2 055 555 C (MARG-I MARGUS M E),				
	10 March 1996 (1996-03-10) abstract				
		-/			
<u> </u>	er documents are listed in the continuation of box C.	X Patent family members are lis	ited in annex.		
	egories of cited documents :	"T" later document published after the	international filing date		
conside "E" earlier do	nt defining the general state of the art which is not and to be of particular relevance ocument but published on or after the International	or priority date and not in conflict dited to understand the principle of invention "X" document of particular relevance; the	with the application but or theory underlying the		
which is	t which may throw doubts on priority claim(s) or	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention			
	nt referring to an oral disclosure, use, exhibition or	cannot be considered to involve a document is combined with one o ments, such combination being of	in inventive step when the ir more other such docu-		
"P" document published prior to the international filing date but		in the art.  "&" document member of the same par	•		
Date of the at	ctual completion of the international search	Date of mailing of the international	search report		
	April 2002	<u> </u>	02		
Name and ma	alling address of the ISA  European Patent Office, P.B. 5818 Patentian 2	Authorized officer			
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Jochheim, J			

Form PCT/ISA/210 (second sheet) (July 1992)

PCT7NL 02/00012

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT						
ategory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.				
X	DE 24 26 757 A (GUENTHER NORBERT ARMIN) 11 December 1975 (1975-12-11) page 2, paragraphs 2,3 page 5, paragraph 3	1				
	· · ·					
		÷				
			·			
			·			

PCT/NL 02/00012

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1998)

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claim : 1

Method for the production of contact lenses

2. Claims: 2-8

Composition for the impregnation of a contact lens

3. Claim: 9

Contact lens for treatment and/or care and/or protection of the eye

4. Claim: 10

Kit for the production of contact lenses

5. Claims: 11-14

Method for the treatment and/or care and/or protection of the eye

6. Claim: 15

Composition for disinfection and/or conservation of contact lenses

PCT77L 02/00012

	Publication date		Patent family member(s)	Publication date
Α	28-02-1988	SU	1377104 A1	28-02-1988
С	10-03-1996	RU	2055555 C1	10-03-1996
Α	11-12-1975	DE	2426757 A1	11-12-1975
	A C A	A 28-02-1988 C 10-03-1996	A 28-02-1988 SU C 10-03-1996 RU	A 28-02-1988 SU 1377104 A1 C 10-03-1996 RU 2055555 C1

Form PCT/ISA/210 (patent family annex) (July 1992)